A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma

被引：0
|
作者：
Campos, S. [1 ]
Penson, R. [2 ]
Berlin, S. [3 ]
Matulonis, U. [3 ]
Horowitz, N. [3 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [31] Phase II study of clinical activity of pegaspargase in women with relapsed or refractory epithelial ovarian, fallopian tube, and/or primary peritoneal cancer
    Kim, G.
    Squires, J.
    Yu, M.
    Walker, A.
    Houston, N. D.
    Otten, L.
    Kohn, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study
    Tew, William P.
    Sill, Michael W.
    Walker, Joan L.
    Secord, Angeles Alvarez
    Bonebrake, Albert J.
    Schilder, Jeanne M.
    Stuckey, Ashley
    Rice, Laurel
    Tewari, Krishnansu S.
    Aghajanian, Carol A.
    GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 257 - 263
  • [33] PHASE I/II STUDY OF CARBOPLATIN AND PRALATREXATE IN PATIENTS WITH RECURRENT PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
    del Carmen, M.
    Campos, S.
    Krasner, C.
    Berlin, S.
    Supko, J.
    Atkinson, T.
    Birrer, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 419 - 420
  • [34] Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
    Pecorelli, S.
    Ray-Coquard, I.
    Tredan, O.
    Colombo, N.
    Parma, G.
    Tisi, G.
    Katsaros, D.
    Lhomme, C.
    Lissoni, A. A.
    Vermorken, J. B.
    du Bois, A.
    Poveda, A.
    Frigerio, L.
    Barbieri, P.
    Carminati, P.
    Brienza, S.
    Guastalla, J. P.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 759 - 765
  • [35] EFFECTIVENESS OF ORAL ETOPOSIDE IN RECURRENT OR REFRACTORY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CANCER AND FALLOPIAN TUBE CANCER
    Kongsawatvorakul, C.
    Charakorn, C.
    Chittithaworn, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 742 - 742
  • [36] Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer
    Kongsawatvorakul, Chompunoot
    Charakorn, Chuenkamon
    Chittithaworn, Suwicha
    Lertkhachonsuk, Arb-Aroon
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 42 (06) : 2331 - 2335
  • [37] Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma
    Hoffman, MA
    Blessing, JA
    Morgan, M
    GYNECOLOGIC ONCOLOGY, 2000, 79 (03) : 463 - 465
  • [38] Resection of recurrent ovarian or fallopian tube carcinoma involving the liver
    Yoon, SS
    Jarnagin, WR
    Fong, Y
    DeMatteo, RP
    Barakat, RR
    Blumgart, LH
    Chi, DS
    GYNECOLOGIC ONCOLOGY, 2003, 91 (02) : 383 - 388
  • [39] A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
    Vasey, P. A.
    Gore, M.
    Wilson, R.
    Rustin, G.
    Gabra, H.
    Guastalla, J-P
    Lauraine, E. P.
    Paul, J.
    Carty, K.
    Kaye, S.
    BRITISH JOURNAL OF CANCER, 2008, 98 (11) : 1774 - 1780
  • [40] A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
    P A Vasey
    M Gore
    R Wilson
    G Rustin
    H Gabra
    J-P Guastalla
    E P Lauraine
    J Paul
    K Carty
    S Kaye
    British Journal of Cancer, 2008, 98 : 1774 - 1780
12345